ASF Standards · Hospital · Standard 14
Standard 14 — Oncology & Cancer Care
Criteria in this standard
14.1 — Cytotoxic Drug Handling Follows a Verified Safe-Handling Standard
14.2 — Chemotherapy Dose Is Verified by Independent Two-Person Check
14.3 — Neutropenic Fever Triggers an Immediate, Time-Bound Response
14.4 — Extravasation Is Recognised and Managed Immediately
14.5 — Multidisciplinary Tumor Board Informs Treatment Planning
14.6 — Palliative Care Integrated Alongside Active Treatment
14.2 — Chemotherapy Dose Is Verified by Independent Two-Person Check
14.3 — Neutropenic Fever Triggers an Immediate, Time-Bound Response
14.4 — Extravasation Is Recognised and Managed Immediately
14.5 — Multidisciplinary Tumor Board Informs Treatment Planning
14.6 — Palliative Care Integrated Alongside Active Treatment
14.1
Cytotoxic Drug Handling Follows a Verified Safe-Handling Standard
Non-Negotiable
Preparation, administration, and disposal of cytotoxic and other hazardous drugs follows a defined, verified safe-handling standard — appropriate personal protective equipment, engineering controls, and disposal procedures — not informal practice that varies by individual staff member, including on inpatient wards where chemotherapy may be administered outside the dedicated infusion unit.
In plain terms: Cytotoxic drugs are handled safely and consistently everywhere they’re actually used in the hospital — not just in the dedicated oncology unit, with ward nurses left to improvise.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
A hospital’s chemotherapy safe-handling practice can look solid in the dedicated oncology or infusion unit, while quietly breaking down the moment a patient receiving chemotherapy is on a general ward — for a complication, a combined admission, or simply overflow capacity — and ward nursing staff who handle it only occasionally lack the specific, consistent training and equipment access that unit-based staff take for granted. This gap is precisely what this criterion is built to catch, since hazardous drug exposure risk doesn’t diminish just because the drug is being given somewhere other than the usual unit.
What good looks like
- PPE is used consistently by ward staff, not only the dedicated infusion unit.
- Required engineering controls are used wherever preparation actually happens.
- A compliant hazardous waste pathway exists on every unit where it’s generated.
Common failure modes
- Safe handling is strong in the oncology unit but weak on general wards.
- Ward staff lack specific training or ready access to required PPE.
- Hazardous waste from off-unit administration goes into general medical waste.
Worked example
In practice
A patient receiving chemotherapy while admitted to a general medical ward for an unrelated infection.
BeforeThe oncology unit’s safe-handling practice was excellent, but when this patient’s scheduled chemotherapy was given on the general ward to avoid transfer, the ward nurses had never received chemotherapy-specific handling training and used standard gloves rather than chemotherapy-rated PPE.
ActionThe hospital built mandatory chemotherapy safe-handling training for all nursing staff, not just the oncology unit, with PPE and disposal supplies stocked on every ward with a defined protocol for exactly this off-unit administration scenario.
AfterThe Monitor reviewed a subsequent off-unit administration and found ward staff using correct PPE with documented training completion. Criterion verified.
If you are starting from zero — do this first
- Check whether chemotherapy is ever administered outside the dedicated unit.
- Extend safe-handling training to all relevant nursing staff, not only the oncology unit.
- Stock required PPE and disposal supplies on any unit where off-unit administration occurs.
The most common mistake: Strong safe-handling practice in the dedicated oncology unit that quietly breaks down whenever chemotherapy needs to be administered on a general ward, where staff lack the same specific training and equipment access.
Self-assessment questions
1. Is appropriate personal protective equipment used consistently for every stage of handling, including by inpatient ward nursing staff, not only dedicated infusion unit staff? — Consistent use at every stage and location, not only in the specialized infusion setting.
Evidence: PPE usage observation and training records
Evidence: PPE usage observation and training records
2. Are hazardous drugs prepared and stored using the required engineering controls, not standard pharmacy equipment? — Specific, required controls, not general pharmacy practice assumed to be sufficient.
Evidence: Pharmacy preparation area inspection
Evidence: Pharmacy preparation area inspection
3. Is hazardous waste disposed of through a defined, compliant pathway on every inpatient unit where it’s generated, not general medical waste? — A specific, separate disposal pathway matched to the actual risk, available wherever cytotoxic agents are actually used.
Evidence: Waste disposal record
Evidence: Waste disposal record
Common reasons for a PARTIAL answer
- Training and supplies are strong in the oncology unit but inconsistent on general wards.
- No specific protocol exists for off-unit chemotherapy administration scenarios.
Implementation plan
| When | What |
|---|---|
| Week 1 | Check whether off-unit chemotherapy administration occurs. |
| Week 2 | Extend safe-handling training hospital-wide for relevant staff. |
| Week 3 | Stock required PPE and disposal supplies on relevant units. |
| Ongoing | Spot-check any off-unit administration for consistent safe practice. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| OBSERVE | Multi-unit inspection | Observes safe-handling practice both in the dedicated unit and on a general ward if off-unit administration occurs. |
Evidence base
World Health Organization. WHO Guidelines on Hand Hygiene and Hazardous Drug Handling in Health Care. Geneva: WHO; 2019.
14.2
Chemotherapy Dose Is Verified by Independent Two-Person Check
Non-Negotiable
Every chemotherapy dose, drug, route, and infusion rate is independently verified by two qualified individuals before administration, each forming their own judgement separately — not a single check followed by a second signature, and applied identically on inpatient wards as in the dedicated oncology unit.
In plain terms: Every chemotherapy dose is genuinely double-checked by two people working independently — not one person checking and a second just signing off — wherever in the hospital it’s actually given.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
A second signature that simply confirms the first person’s already-formed conclusion provides considerably less genuine protection than two people independently forming their own judgement from the original order — the entire value of a double-check lies in two genuinely separate assessments, not a sequential rubber stamp. This matters identically regardless of which unit the chemotherapy happens to be given on; an exception made for “perceived routine” cases, or for administration outside the usual oncology unit, undermines the safeguard precisely where consistency matters most.
What good looks like
- Every dose undergoes genuine independent verification by two qualified individuals.
- Each person forms their own separate judgement, not a confirmatory signature.
- Verification covers drug, dose, route, and infusion rate together.
Common failure modes
- A “routine” case is exempted from full independent double-checking.
- The second check is a signature confirming the first, not a genuine separate assessment.
- Verification covers dose alone, missing route or rate errors.
Worked example
In practice
A hospital reviewing its double-check practice across units.
BeforeIn the dedicated oncology unit, two nurses genuinely independently calculated and verified each dose. On the general ward, where chemotherapy was occasionally given, one nurse calculated the dose and a second simply co-signed without independently recalculating.
ActionThe hospital standardized the independent verification process hospital-wide, requiring both verifiers to calculate independently from the original order before comparing results, with training extended to any staff who might administer chemotherapy off-unit.
AfterThe Monitor observed a general ward chemotherapy administration and confirmed both nurses performed genuinely independent calculations before comparing. Criterion verified.
If you are starting from zero — do this first
- Check whether double-checking is genuinely independent or a confirmatory signature.
- Build a process requiring independent calculation before comparison.
- Standardize this process identically across every unit where chemotherapy is given.
The most common mistake: A genuine independent double-check in the dedicated oncology unit that degrades into a confirmatory signature on a general ward, where the second verifier simply co-signs rather than independently recalculating from the original order.
Self-assessment questions
1. Does every chemotherapy dose undergo independent verification by two qualified individuals before administration, on every unit where it’s given? — Two people, every dose, without exception for perceived routine cases or off-unit administration.
Evidence: Verification record
Evidence: Verification record
2. Does each person form their own separate judgement, not simply confirm the first person’s check? — Genuine independence, not sequential confirmation of the same conclusion.
Evidence: Direct observation of the verification process
Evidence: Direct observation of the verification process
3. Does verification specifically cover drug, dose, route, and infusion rate together, not dose alone? — All four elements, since an error in any one carries real risk.
Evidence: Verification checklist content
Evidence: Verification checklist content
Common reasons for a PARTIAL answer
- Independent verification is strong on the dedicated unit but weaker on general wards.
- Verification covers dose but not consistently route and rate.
Implementation plan
| When | What |
|---|---|
| Week 1 | Observe current double-check practice across relevant units. |
| Week 2 | Build a standardized independent-verification process. |
| Week 3 | Train all relevant staff hospital-wide. |
| Ongoing | Observe verification practice periodically for genuine independence. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| OBSERVE | Direct verification observation | Observes an actual chemotherapy double-check for genuine independence versus confirmatory signature. |
Evidence base
World Health Organization. Patient Safety: Make Health Care Safer. Geneva: WHO; 2021.
14.3
Neutropenic Fever Triggers an Immediate, Time-Bound Response
Non-Negotiable
A patient with suspected neutropenic fever receives first-dose antibiotics within a defined, short time target from presentation, with staff trained to recognize the urgency and a protocol that bypasses routine triage queuing — not treated as a standard fever presentation.
In plain terms: Neutropenic fever genuinely gets treated as the time-critical emergency it is — with antibiotics started fast and real tracking of how fast — not quietly treated as just another fever in the queue.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
Neutropenic fever carries a specific, well-documented time-sensitivity — delay in starting antibiotics measurably worsens outcomes, which is precisely why routine triage queuing, appropriate for a standard fever presentation, represents a genuine and preventable risk here. A general sense that treatment happens “promptly” is considerably less reliable than a specific, measured time target genuinely tracked against actual practice, since the gap between perceived and actual speed can be significant without active measurement.
What good looks like
- A specific, measured time target exists and is genuinely tracked.
- Staff recognize neutropenic fever as time-critical, bypassing standard queuing.
- A documented instance exists with actual time-to-antibiotic data recorded.
Common failure modes
- Treatment speed is assumed adequate without a specific, tracked target.
- A neutropenic fever patient waits in standard triage like any other fever.
- No real example exists showing actual measured time-to-antibiotic data.
Worked example
In practice
An oncology patient presenting to the emergency department with fever.
BeforeA patient on chemotherapy presenting with fever was triaged alongside other fever presentations without specific recognition of neutropenic fever risk, resulting in a wait time before antibiotics that significantly exceeded recommended targets.
ActionThe hospital built a specific neutropenic fever alert triggered by any oncology patient presenting with fever, bypassing standard triage queuing and activating a dedicated rapid antibiotic pathway with a defined time target actively tracked.
AfterThe Monitor reviewed time-to-antibiotic data for recent neutropenic fever presentations and found consistent achievement of the defined target. Criterion verified.
If you are starting from zero — do this first
- Set a specific, defined time-to-antibiotic target.
- Build a neutropenic fever alert bypassing standard triage queuing.
- Build a tracking system for actual time-to-antibiotic data.
The most common mistake: Treating a febrile oncology patient as a routine fever presentation in standard triage, without recognizing the time-critical nature of possible neutropenic fever, resulting in a wait time that significantly exceeds what the patient’s actual risk warrants.
Self-assessment questions
1. Is there a defined, specific time target for first-dose antibiotics from presentation, genuinely tracked against actual practice? — A specific, measured target, not a general sense that treatment happens “promptly.”
Evidence: Time-to-antibiotic tracking data
Evidence: Time-to-antibiotic tracking data
2. Do staff recognize neutropenic fever as a time-critical emergency distinct from routine fever, bypassing standard queuing? — Delay from routine triage treatment is a specific, well-documented risk for this patient population.
Evidence: Alert/bypass protocol
Evidence: Alert/bypass protocol
3. Is there a documented instance of this protocol being used with actual time-to-antibiotic data recorded? — Evidence the protocol genuinely functions, not just exists on paper.
Evidence: Case record with timing data
Evidence: Case record with timing data
Common reasons for a PARTIAL answer
- A target exists but isn’t consistently tracked against real cases.
- Recognition and bypass work in the emergency department but not consistently elsewhere.
Implementation plan
| When | What |
|---|---|
| Week 1 | Set a specific time-to-antibiotic target. |
| Week 2 | Build a neutropenic fever alert and triage-bypass protocol. |
| Week 3 | Build a time-tracking system and brief relevant staff. |
| Ongoing | Review time-to-antibiotic data periodically. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Time-to-antibiotic data review | Reviews actual recorded time-to-antibiotic data for recent neutropenic fever presentations against the defined target. |
Evidence base
World Health Organization. Patient Safety: Make Health Care Safer. Geneva: WHO; 2021.
14.4
Extravasation Is Recognised and Managed Immediately
Core
Staff administering vesicant or irritant chemotherapy agents are specifically trained to recognise early signs of extravasation, with a defined, immediate management protocol and appropriate antidotes genuinely available wherever these agents are administered, including inpatient wards.
In plain terms: Staff genuinely know the early signs of extravasation for the specific drugs they’re actually giving, and the right antidote is actually on hand wherever that drug is administered — not only in the dedicated unit.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
Generic infusion complication awareness is distinct from specific, agent-relevant extravasation recognition — a vesicant agent causing tissue damage requires staff to know exactly what to look for with that particular drug, not a general sense that something might be wrong. If antidotes for a specific vesicant are available in the oncology unit but the same agent is occasionally given on a general ward without matching antidote stock, that specific gap undermines the entire purpose of having the antidote protocol at all.
What good looks like
- Staff are trained on recognition specific to the actual agents used here.
- A defined management protocol is accessible on every unit where the agent is given.
- Appropriate antidotes are genuinely available wherever administration occurs.
Common failure modes
- Training covers general infusion complications, not agent-specific extravasation signs.
- The management protocol exists only in the dedicated unit’s reference materials.
- Antidotes are stocked in the oncology unit but not wherever off-unit administration occurs.
Worked example
In practice
A vesicant agent administered on a general ward during an oncology patient’s unrelated admission.
BeforeThe specific antidote for this vesicant agent was stocked and readily accessible in the oncology unit, but when the same agent needed to be given on the general ward, the antidote wasn’t stocked there, and ward staff weren’t trained on this agent’s specific early extravasation signs.
ActionThe hospital built a protocol requiring the matching antidote to accompany any vesicant agent dispensed for off-unit administration, with a quick-reference card on agent-specific signs provided alongside the medication itself.
AfterThe Monitor reviewed a subsequent off-unit administration and confirmed the matching antidote and reference card accompanied the medication to the ward. Criterion verified.
If you are starting from zero — do this first
- Check whether off-unit vesicant administration currently has matching antidote access.
- Build a protocol pairing antidote dispensing with the agent itself.
- Build agent-specific quick-reference materials for off-unit staff.
The most common mistake: Antidotes and agent-specific training being available in the dedicated oncology unit while the same vesicant agent, occasionally given on a general ward, lacks matching antidote stock and staff training in that other location.
Self-assessment questions
1. Are staff specifically trained to recognise early signs of extravasation for the agents actually used here, including ward nursing staff? — Specific to the actual agents administered, not generic infusion complication awareness.
Evidence: Training record
Evidence: Training record
2. Is there a defined, immediate management protocol for suspected extravasation accessible on every unit? — A specific, known protocol, not improvisation in the moment, available wherever the agent might be given.
Evidence: Accessible protocol documentation
Evidence: Accessible protocol documentation
3. Are appropriate antidotes for the specific vesicant agents used genuinely available wherever administration occurs? — Immediately available and in date on the actual unit, not only in the dedicated oncology area.
Evidence: Antidote stock inspection
Evidence: Antidote stock inspection
Common reasons for a PARTIAL answer
- Antidotes are stocked in the main unit but not consistently for off-unit administration.
- Training is agent-specific in the oncology unit but general elsewhere.
Implementation plan
| When | What |
|---|---|
| Week 1 | Check current antidote access for off-unit administration scenarios. |
| Week 2 | Build a protocol pairing antidote dispensing with the agent. |
| Week 3 | Build agent-specific quick-reference materials for off-unit staff. |
| Ongoing | Spot-check off-unit administration for matching antidote access. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Antidote availability check | Checks antidote availability and matching agent-specific training wherever vesicant agents are actually administered. |
Evidence base
World Health Organization. Patient Safety: Make Health Care Safer. Geneva: WHO; 2021.
14.5
Multidisciplinary Tumor Board Informs Treatment Planning
Core
Complex or newly diagnosed cancer cases are genuinely reviewed by a multidisciplinary tumor board before the treatment plan is finalized, with documented board input actually shaping the plan, not a single treating physician’s decision presented as though it were a team decision.
In plain terms: Complex cancer cases genuinely get real multidisciplinary review before the plan is finalized — with board input actually visible in the plan, not a formality rubber-stamping one physician’s decision.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
A tumor board that meets on schedule but doesn’t substantively engage with the specifics of each case — functioning more as a formality than genuine multidisciplinary deliberation — provides none of the real clinical value that comes from surgery, oncology, radiology, and pathology perspectives genuinely informing a complex treatment decision together. The test of whether a board is functioning is whether documented input can actually be traced to a specific change in the treatment plan, not merely whether the meeting occurred.
What good looks like
- The board meets regularly and genuinely reviews complex or new cases.
- Board input is documented as having actually shaped the treatment plan.
- The board genuinely includes relevant specialties, not token representation.
Common failure modes
- A board exists nominally without substantive case review in practice.
- Board attendance is noted but input isn’t traceable to actual plan changes.
- One specialty dominates discussion with limited genuine input from others.
Worked example
In practice
A hospital reviewing its tumor board’s genuine function.
BeforeThe tumor board met weekly and cases were presented, but discussion was brief and the treating oncologist’s pre-formed plan was typically approved with minimal substantive input from surgery, radiology, or pathology, functioning more as a notification than genuine deliberation.
ActionThe hospital restructured board meetings to require pathology and radiology findings presented first, before the treating physician’s proposed plan, specifically to encourage genuine discussion rather than confirmation of a pre-formed decision.
AfterThe Monitor reviewed recent board minutes and found a specific instance where radiology findings discussed at the board changed the proposed surgical approach. Criterion verified.
If you are starting from zero — do this first
- Observe a current tumor board meeting for genuine, substantive discussion.
- Restructure presentation order to encourage discussion before plan confirmation.
- Build a documentation practice tracing board input to specific plan changes.
The most common mistake: A tumor board that meets on a regular schedule and documents attendance, but functions in practice as a brief notification of an already-decided plan rather than genuine multidisciplinary deliberation that could actually change the proposed course.
Self-assessment questions
1. Does a genuine multidisciplinary tumor board meet regularly and actually review complex or new cases, not exist nominally without real case review? — A board that meets but doesn’t substantively review actual cases provides no real value.
Evidence: Board meeting minutes
Evidence: Board meeting minutes
2. Is board input documented as having actually shaped the treatment plan, not just noted as having occurred? — A documented instance where discussion specifically changed the plan is a real test of genuine function.
Evidence: Input-to-plan traceability
Evidence: Input-to-plan traceability
3. Does the board genuinely include relevant specialties — surgery, oncology, radiology, pathology — not a single specialty consulting nominally with others? — Real multidisciplinary input, not one discipline dominating with token representation from others.
Evidence: Attendance and participation record
Evidence: Attendance and participation record
Common reasons for a PARTIAL answer
- The board meets with good attendance but discussion is brief and non-substantive.
- Input is noted in minutes but not clearly traceable to actual plan changes.
Implementation plan
| When | What |
|---|---|
| Week 1 | Observe a current tumor board meeting for genuine engagement. |
| Week 2 | Restructure presentation order to encourage discussion. |
| Week 3 | Build a documentation practice tracing input to plan changes. |
| Ongoing | Review board minutes periodically for substantive discussion evidence. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| OBSERVE | Board meeting observation | Observes a tumor board meeting directly for genuine multidisciplinary engagement versus formality. |
Evidence base
World Health Organization. Guide to Cancer Early Diagnosis. Geneva: WHO; 2017.
14.6
Palliative Care Integrated Alongside Active Treatment
Standard
Palliative care expertise is genuinely integrated early in the course of serious cancer diagnoses, alongside active treatment, not introduced only once active treatment has been exhausted — with symptom management and goals-of-care conversations happening throughout, not as a late, separate referral.
In plain terms: Palliative care genuinely starts early, alongside active treatment, not held back until there’s nothing more to try — with real, ongoing conversations about what matters to the patient, not one late discussion.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
Palliative care introduced only once active treatment options are exhausted misses the real, distinct benefit early integration provides — genuine symptom management and quality-of-life support that’s valuable throughout the treatment course, not only at its end. A single late goals-of-care conversation, held only once options have significantly narrowed, misses the ongoing value of these conversations happening at meaningful points throughout, when the patient and family have more genuine opportunity to process and participate in decisions.
What good looks like
- Palliative care is genuinely introduced early, alongside active treatment.
- Goals-of-care conversations happen at meaningful points throughout the course.
- Palliative referral is genuinely accessible and actually used.
Common failure modes
- Palliative care is introduced only once active treatment is exhausted.
- Goals-of-care conversations happen once, late, rather than ongoing.
- Palliative referral exists but is rarely actually used in practice.
Worked example
In practice
A patient with a serious new cancer diagnosis beginning active treatment.
BeforePalliative care was mentioned only once active treatment options had been fully exhausted, framed to the patient as a sign that nothing more could be done, missing months of potential symptom management and quality-of-life support available earlier in the course.
ActionThe hospital built a routine early palliative care consultation for any serious new cancer diagnosis, explicitly framed as support alongside active treatment, with scheduled goals-of-care check-ins at defined points throughout the course.
AfterThe Monitor reviewed a recent patient’s record and found an early palliative consultation documented alongside the start of active treatment, with ongoing goals-of-care conversations at subsequent points. Criterion verified.
If you are starting from zero — do this first
- Build a routine early palliative care consultation trigger for serious diagnoses.
- Explicitly frame palliative care as alongside, not after, active treatment.
- Build scheduled goals-of-care check-in points throughout the course.
The most common mistake: Introducing palliative care only once active treatment options are fully exhausted, which misses the real, distinct value of early symptom management and quality-of-life support and can unintentionally frame the referral as a signal of abandoned hope rather than ongoing support.
Self-assessment questions
1. Is palliative care genuinely introduced early, alongside active treatment, not only after active treatment options are exhausted? — Early integration provides real symptom and quality-of-life benefit distinct from end-of-life care alone.
Evidence: Palliative consultation timing record
Evidence: Palliative consultation timing record
2. Are goals-of-care conversations happening at meaningful points throughout the course, not deferred to a single late conversation? — Ongoing, not a one-time discussion held only when options have narrowed.
Evidence: Goals-of-care conversation log
Evidence: Goals-of-care conversation log
3. Is palliative referral genuinely accessible and actually used, not a resource that exists on paper but is rarely accessed? — Verified against actual recent use, not only the existence of a palliative care service.
Evidence: Referral usage data
Evidence: Referral usage data
Common reasons for a PARTIAL answer
- Palliative care is available but introduced later than genuinely early.
- Goals-of-care conversations happen but not on a genuinely ongoing basis.
Implementation plan
| When | What |
|---|---|
| Week 1 | Review current palliative referral timing patterns. |
| Week 2 | Build an early referral trigger for serious diagnoses. |
| Week 3 | Build scheduled goals-of-care check-in points. |
| Ongoing | Review referral timing and usage data periodically. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Referral timing review | Reviews palliative consultation timing relative to diagnosis and active treatment start for recent patients. |
Evidence base
World Health Organization. Palliative Care. Geneva: WHO; 2020.